focus -WSS

focus

author：knowledge 2025-09-03 09:35:36 - browse：25492

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Medicare to cover more brain scans for Alzheimer’s patients

WSS

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Longer MASH drug regimen improved liver, Akero study finds

The public health thinking behind the CDC’s new Covid guidance

Families look for replacement for GSK asthma drug Flovent

Change Healthcare: What is it, why does its cyberattack matter?

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Heart attack and stroke risk calculators need revising

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Malaria cases in Florida and Texas: Here’s what you need to know

$1 billion proposal to grow Boston, Massachusetts biotech

Virginia high school admissions case could be legal follow

Medicare has a new plan to address drug shortages

United colonoscopy coverage change 'may cost lives,' doctors say

Startup Neumora takes a novel depression drug to Phase 3

Jerome Adams on the need for new antivirals for Covid

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Wikipedia

The untold story of TV’s first prescription drug ad

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Cosmetics set for new safety regulation. Why the industry is on board

Ancient Greek ideas underpin modern concepts of pregnancy

Immune cells and nerve overgrowth may explain recurring UTI pain

For AI in health care standards, federal regulators join with industry group

explore

entertainment

Wikipedia

hotspot